Bente M Houtman, Iris Walraven, Elke de Grouw, Richard W M van der Maazen, Leontien C M Kremer, Eline van Dulmen-den Broeder, Marry M van den Heuvel-Eibrink, Wim J E Tissing, Dorine Bresters, Helena J H van der Pal, Andrica C H de Vries, Marloes Louwerens, Margriet van der Heiden-van der Loo, Sebastian J C Neggers, Geert O Janssens, Nicole M A Blijlevens, Annechien J A Lambeck, Frank Preijers, Jacqueline J Loonen
{"title":"IgM记忆B细胞在评估有脾功能异常风险的癌症儿童幸存者脾功能中的价值：DCCSS-LATER研究。","authors":"Bente M Houtman, Iris Walraven, Elke de Grouw, Richard W M van der Maazen, Leontien C M Kremer, Eline van Dulmen-den Broeder, Marry M van den Heuvel-Eibrink, Wim J E Tissing, Dorine Bresters, Helena J H van der Pal, Andrica C H de Vries, Marloes Louwerens, Margriet van der Heiden-van der Loo, Sebastian J C Neggers, Geert O Janssens, Nicole M A Blijlevens, Annechien J A Lambeck, Frank Preijers, Jacqueline J Loonen","doi":"10.1155/2023/5863995","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Childhood cancer survivors (CCS) who received radiotherapy involving the spleen or total body irradiation (TBI) might be at risk for splenic dysfunction. A comprehensive screening test for examining splenic dysfunction is lacking.</p><p><strong>Objective: </strong>We investigated whether IgM memory B-cells could be used to assess splenic dysfunction in CCS who received a splenectomy, radiotherapy involving the spleen, or TBI.</p><p><strong>Methods: </strong>All CCS were enrolled from the DCCSS-LATER cohort. We analyzed differences in IgM memory B-cells and Howell-Jolly bodies (HJB) in CCS who had a splenectomy (<i>n</i> = 9), received radiotherapy involving the spleen (<i>n</i> = 36), or TBI (<i>n</i> = 15). IgM memory B-cells < 9 cells/<i>µ</i>L was defined as abnormal.</p><p><strong>Results: </strong>We observed a higher median number of IgM memory B-cells in CCS who received radiotherapy involving the spleen (31 cells/<i>µ</i>L, <i>p</i>=0.06) or TBI (55 cells/<i>µ</i>L, <i>p</i> = 0.03) compared to CCS who received splenectomy (20 cells/<i>µ</i>L). However, only two CCS had IgM memory B-cells below the lower limit of normal. No difference in IgM memory B-cells was observed between CCS with HJB present and absent (35 cells/<i>µ</i>L vs. 44 cells/<i>µ</i>L).</p><p><strong>Conclusion: </strong>Although the number of IgM memory B-cells differed between splenectomized CCS and CCS who received radiotherapy involving the spleen or TBI, only two CCS showed abnormal values. Therefore, this assessment cannot be used to screen for splenic dysfunction.</p>","PeriodicalId":15952,"journal":{"name":"Journal of Immunology Research","volume":"2023 ","pages":"5863995"},"PeriodicalIF":3.5000,"publicationDate":"2023-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10611543/pdf/","citationCount":"0","resultStr":"{\"title\":\"The Value of IgM Memory B-Cells in the Assessment of Splenic Function in Childhood Cancer Survivors at Risk for Splenic Dysfunction: A DCCSS-LATER Study.\",\"authors\":\"Bente M Houtman, Iris Walraven, Elke de Grouw, Richard W M van der Maazen, Leontien C M Kremer, Eline van Dulmen-den Broeder, Marry M van den Heuvel-Eibrink, Wim J E Tissing, Dorine Bresters, Helena J H van der Pal, Andrica C H de Vries, Marloes Louwerens, Margriet van der Heiden-van der Loo, Sebastian J C Neggers, Geert O Janssens, Nicole M A Blijlevens, Annechien J A Lambeck, Frank Preijers, Jacqueline J Loonen\",\"doi\":\"10.1155/2023/5863995\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Childhood cancer survivors (CCS) who received radiotherapy involving the spleen or total body irradiation (TBI) might be at risk for splenic dysfunction. A comprehensive screening test for examining splenic dysfunction is lacking.</p><p><strong>Objective: </strong>We investigated whether IgM memory B-cells could be used to assess splenic dysfunction in CCS who received a splenectomy, radiotherapy involving the spleen, or TBI.</p><p><strong>Methods: </strong>All CCS were enrolled from the DCCSS-LATER cohort. We analyzed differences in IgM memory B-cells and Howell-Jolly bodies (HJB) in CCS who had a splenectomy (<i>n</i> = 9), received radiotherapy involving the spleen (<i>n</i> = 36), or TBI (<i>n</i> = 15). IgM memory B-cells < 9 cells/<i>µ</i>L was defined as abnormal.</p><p><strong>Results: </strong>We observed a higher median number of IgM memory B-cells in CCS who received radiotherapy involving the spleen (31 cells/<i>µ</i>L, <i>p</i>=0.06) or TBI (55 cells/<i>µ</i>L, <i>p</i> = 0.03) compared to CCS who received splenectomy (20 cells/<i>µ</i>L). However, only two CCS had IgM memory B-cells below the lower limit of normal. No difference in IgM memory B-cells was observed between CCS with HJB present and absent (35 cells/<i>µ</i>L vs. 44 cells/<i>µ</i>L).</p><p><strong>Conclusion: </strong>Although the number of IgM memory B-cells differed between splenectomized CCS and CCS who received radiotherapy involving the spleen or TBI, only two CCS showed abnormal values. Therefore, this assessment cannot be used to screen for splenic dysfunction.</p>\",\"PeriodicalId\":15952,\"journal\":{\"name\":\"Journal of Immunology Research\",\"volume\":\"2023 \",\"pages\":\"5863995\"},\"PeriodicalIF\":3.5000,\"publicationDate\":\"2023-10-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10611543/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Immunology Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1155/2023/5863995\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Immunology Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1155/2023/5863995","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
The Value of IgM Memory B-Cells in the Assessment of Splenic Function in Childhood Cancer Survivors at Risk for Splenic Dysfunction: A DCCSS-LATER Study.
Background: Childhood cancer survivors (CCS) who received radiotherapy involving the spleen or total body irradiation (TBI) might be at risk for splenic dysfunction. A comprehensive screening test for examining splenic dysfunction is lacking.
Objective: We investigated whether IgM memory B-cells could be used to assess splenic dysfunction in CCS who received a splenectomy, radiotherapy involving the spleen, or TBI.
Methods: All CCS were enrolled from the DCCSS-LATER cohort. We analyzed differences in IgM memory B-cells and Howell-Jolly bodies (HJB) in CCS who had a splenectomy (n = 9), received radiotherapy involving the spleen (n = 36), or TBI (n = 15). IgM memory B-cells < 9 cells/µL was defined as abnormal.
Results: We observed a higher median number of IgM memory B-cells in CCS who received radiotherapy involving the spleen (31 cells/µL, p=0.06) or TBI (55 cells/µL, p = 0.03) compared to CCS who received splenectomy (20 cells/µL). However, only two CCS had IgM memory B-cells below the lower limit of normal. No difference in IgM memory B-cells was observed between CCS with HJB present and absent (35 cells/µL vs. 44 cells/µL).
Conclusion: Although the number of IgM memory B-cells differed between splenectomized CCS and CCS who received radiotherapy involving the spleen or TBI, only two CCS showed abnormal values. Therefore, this assessment cannot be used to screen for splenic dysfunction.
期刊介绍：
Journal of Immunology Research is a peer-reviewed, Open Access journal that provides a platform for scientists and clinicians working in different areas of immunology and therapy. The journal publishes research articles, review articles, as well as clinical studies related to classical immunology, molecular immunology, clinical immunology, cancer immunology, transplantation immunology, immune pathology, immunodeficiency, autoimmune diseases, immune disorders, and immunotherapy.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
